Despite these differences both molecules have strikingly similar impacts on PI3Kα signaling across a range of cell types including both RAS mutant and HER2 overexpressing models and inhibit tumor growth in vivo without inducing hyperglycemia. The gene discussed is ERBB2; the disease is neoplasm.